1. Tack J, et al. Functional gastroduodenal disorders. Gastroenterology. 2006; 130: 1466-1479.
2. Hirakawa K, et al. Prevalence of non-ulcer dyspepsia in the Japanese population. J Gastroenterol Hepatol. 1999; 14: 1083-1087.
3. Kawamura A, et al. Prevalence of functional dyspepsia and its relationship with Helicobacter pylori infection in a Japanese population. J Gastroenterol Hepatol. 2001; 16: 384-388.
4. Haycox A, Einarson T, Eggleston A. The health economic impact of upper gastrointestinal symptoms in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol. 1999; 231: 38-47.
5. Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther. 2004; 20: 31-39.
6. Kinoshita Y, et al. Characteristics of japanese patients with chronic gastritis and comparison with functional dyspepsia defined by Rome III criteria: based on the large- scale survey, FUTURE study. Intern Med. 2011; 50: 2269-2276.
7. Stanghellini V, Chan F K, Hasler W L, et al. Gastroduodenal disorders. Gastroenterology. 2016; 150: 1380-1392.
8. Vakil, N., et al. Symptom overlap between postprandial distress and epigastric pain syndromes of the Rome III dyspepsia classification. Am J Gastroenterol. 2013; 108(5): 767-774.
9. Bisschops R, Karamanolis G, Arts J, et al. Relationship between symptoms and ingestion of a meal in functional dyspepsia. Gut. 2008; 57: 1495-1503.
10. 木下芳一, 天野祐二. 内視鏡的胃炎と上腹部症状の関係. 日消誌. 2007; 104: 1573-1579.
11. Moayyedi P. Helicobacter pylori eradication for functional dyspepsia: what are we treating?: comment on “Helicobacter pylori eradication in functional dyspepsia”. Arch Intern Med. 2011; 171: 1936-1937.
12. Kaji M, Fujiwara Y, Shiba M, et al. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol. 2010; 25: 1151-1156.
13. Oshima T, Okugawa T, Tomita T, et al. Generation of dyspeptic symptoms by direct acid and water infusion into the stomachs of functional dyspepsia patients and healthy subjects. Aliment Pharmacol Ther. 2012; 35: 175-182.
14. Lee KJ, Demarchi B, Demedts I, et al. A pilot study on duodenal acid exposure and its relationship to symptoms in functional dyspepsia with prominent nausea. Am J Gastroenterol. 2004; 99: 1765-1773.
15. Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006; CD001960.
16. 機能性消化管疾患診療ガイドライン 2014-機能性ディスペプシア (FD). 日本消化器病学会編, 南江堂, 東京, 2014.
17. Pinto-Sanchez MI, Yuan Y, Hassan A, et al. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017; 11: CD011194.
18. Suzuki H, Kusunoki H, Kamiya T, et al. Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): A multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial. United European Gastroenterol J. 2013; 1: 445-452.
19. Samsom M, Verhagen MA, vanBergeHenegouwen GP, et al. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology. 1999; 116: 515-520.
20. Holtmann G, Goebell H, Jockenhoevel F, et al. Altered vagal and intestinal mechanosensory function in chronic unexplained dyspepsia. Gut. 1998; 42: 501-506.
21. Ito H, Iijima K, Ara N, et al. Reactive nitrogen oxide species induce dilatation of the intercellular space of rat esophagus. Scand J Gastroenterol. 2010; 45: 282-291.
22. Ara N, Iijima K, Asanuma K, et al. Disruption of gastric barrier function by luminal nitrosative stress: a potential chemical insult to the human gastro-oesophageal junction. Gut. 2008; 57: 306-313.
23. Honda J, Iijima K, Asanuma K, et al. Estrogen enhances esophageal barrier function by potentiating occludin expression. Dig Dis Sci. 2016; 61: 1028-1038.
24. Vanheel H, Vicario M, Vanuytsel T, et al. Impaired duodenal mucosal integrity and low- grade inflammation in functional dyspepsia. Gut. 2014; 63: 262-271.
25. Vanheel H, Vicario M, et al. Activation of eosinophils and mast cells in functional dyspepsia: an ultrastructural evaluation. Scientific Report. 2018; 8: 5383.
26. Svedlund J, Sjödin I, Dotevall G. GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988; 33: 129-134.
27. Dimenäs E, Glise H, Hallerbäck B, et al. Well- Being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol. 1995; 30: 1046-1052.
28. Halling K. · Kulich K. · Carlsson J. et al. An international comparison of the burden of Illness in patients with dyspepsia. Digestive Diseases Dig Dis. 2008; 26: 264–273.
29. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969; 1: 87-97.
30. Toshihisa Takeuchi, Takahisa Furuta, et al. Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study). Aliment Pharmacol Ther. 2020; 51: 534-543.
31. Welen K, Faresjo A, Faresjo T. Functional dyspepsia affects women more than men in daily life: a case-control study in primary care. Gend Med. 2008; 5: 62-73.
32. Kim SE, Kim N, Lee JY, et al. Prevalence and Risk Factors of Functional Dyspepsia in Health Check-up Population: A Nationwide Multicenter Prospective Study. J Neurogastroenterol Motil. 2018; 24: 603-613.
33. Lucas Wauters, Nicholas J Talley, et al. Novel concepts in the pathophysiology and treatment of functional dyspepsia. Gut. 2020; 69: 591-600.
34. Vanheel H, Farré R. Changes in gastrointestinal tract function and structure in functional dyspepsia. Nat Rev Gastroenterol Hepatol. 2013; 10: 142-149.
35. Cheng E, Zhang X, Huo X, et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut. 2013; 62: 824-832.
36. Ishimura N, et al. Sustained acid suppression by potassium-competitive acid blocker(P-CAB) may be an attractive treatment candidate for patients with eosinophilic esophagitis. Am J Gastroenterol. 2016; 111: 1203-1204.
37. Futagami S, Shindo T, Kawagoe T, et al. Migration of eosinophils and CCR2-CD68-double positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia. Am J Gastroenterol. 2010; 105: 1835-1842.
38. van Rhijn BD, Weijenborg PW, Verheij J, et al. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2014; 12: 1815- 1823.
39. Rocco MZ, Graham RL, Lorenzo F, et.al. Epidemiology of functional dyspepsia and subgroups in the Italian general population: an endoscopic study. Gastroenterology. 2010; 138: 1302-1311.